Keck School Faculty

Diana Lewez Hanna

Diana Lewez Hanna

Assistant Professor of Clinical Medicine
One Hoag Drive, Cancer Center, 3rd Floor Off Campus Newport Beach

Division of Oncology, USC: Chief Fellow, 2014-2015

University of California, Davis: Professionalism of the Year in Internal Medicine Award, 2012

: Phi Sigma Honor Society, 2005

: Phi Kappa Phi Honor Society, 2005

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study Lancet Oncol. 2022 Dec; 23(12):1558-1570. . View in PubMed

Cabozantinib: An evolving therapy for hepatocellular carcinoma Cancer Treat Rev. 2021 Jul; 98:102221. . View in PubMed

The time to offer treatments for COVID-19 Expert Opin Investig Drugs. 2021 May; 30(5):505-518. . View in PubMed

The Importance of Understanding the Stages of COVID-19 in Treatment and Trials AIDS Rev. 2021 02 08; 23(1):40-47. . View in PubMed

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients Cancers (Basel). 2020 Oct 13; 12(10). . View in PubMed

How we treat left-sided vs right-sided colon cancer Clin Adv Hematol Oncol. 2020 May; 18(5):253-257. . View in PubMed

Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib Cancer Sci. 2020 Feb; 111(2):441-450. . View in PubMed

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials Eur J Cancer. 2020 05; 131:89-97. . View in PubMed

Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer Oncotarget. 2019 Dec 17; 10(66):7016-7030. . View in PubMed

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study Clin Colorectal Cancer. 2018 09; 17(3):e471-e488. . View in PubMed

Prognostic impact of FOXF1 polymorphisms in gastric cancer patients Pharmacogenomics J. 2018 04; 18(2):262-269. . View in PubMed

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients Pharmacogenomics J. 2018 01; 18(1):29-34. . View in PubMed

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab Clin Cancer Res. 2018 02 15; 24(4):784-793. . View in PubMed

Colorectal cancer: epigenetic alterations and their clinical implications Biochim Biophys Acta Rev Cancer. 2017 Dec; 1868(2):439-448. . View in PubMed

DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer Cancer. 2017 Oct 01; 123(19):3732-3743. . View in PubMed

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy Pharmacogenomics J. 2017 12; 17(6):543-550. . View in PubMed

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials Eur J Cancer. 2017 05; 77:13-20. . View in PubMed

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial Int J Cancer. 2017 07 15; 141(2):383-392. . View in PubMed

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012 Oncotarget. 2016 Aug 16; 7(33):53668-53678. . View in PubMed

Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment Clin Cancer Res. 2016 Aug 15; 22(16):3999-4004. . View in PubMed

Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1091-108. . View in PubMed

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Mol Cancer Ther. 2016 11; 15(11):2814-2821. . View in PubMed

TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy Mol Cancer Ther. 2016 06; 15(6):1405-11. . View in PubMed

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 ESMO Open. 2016; 1(5):e000097. . View in PubMed

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy Clin Cancer Res. 2016 07 01; 22(13):3218-26. . View in PubMed

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Mol Cancer Ther. 2015 Oct; 14(10):2401-8. . View in PubMed

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy Pharmacogenomics J. 2015 Aug; 15(4):354-62. . View in PubMed

Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis Cancer. 2014 Dec 01; 120(23):3707-16. . View in PubMed

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy Mol Cancer Ther. 2014 Feb; 13(2):528-39. . View in PubMed

Biomolecular markers of cancer-associated thromboembolism Crit Rev Oncol Hematol. 2013 Oct; 88(1):19-29. . View in PubMed

Dr. Hanna's research interests include investigation of predictive and prognostic biomarkers in gastrointestinal malignancies and clinical trial protocol development with Dr. Heinz-Josef Lenz.

Dr. Hanna earned her medical degree from University of California, Davis. She then went on to complete her Hematology/Oncology Fellowship at USC, where she served as Chief Fellow.
sc ctsi logoPowered by SC CTSI